BioReliance Corporation

14920 Broschart Road
Rockville
Maryland
20850
United States

Tel: 800-553-5372
Fax: 301-610-2590

About BioReliance Corporation

BioReliance is the leading provider of GLP and cGMP compliant contract services supporting testing, development and manufacturing of biologics worldwide. Founded in 1947 as Microbiological Associates, BioReliance has operations in the United States, United Kingdom and Germany.

Products and services:
BioReliance testing services include: characterization of cell banks, release testing of bulk and final product, viral and DNA clearance studies, analytical services, genetic, mammalian and molecular toxicology, biodistribution studies and comprehensive testing for laboratory animals including serology and PCR testing on rodent and simian species.

BioReliance offers contract manufacturing services for mammalian cell derived viral therapeutics and agents expressed in E.coli and yeast. A full range of services is offered from process development, scale-up and qualification, bulk drug production, aseptic filling and final drug packaging. Regulatory support services include the preparation of Chemistry Manufacturing and Controls (CMC) sections of regulatory filings.
Last Updated: 05-01-2007

38 articles about BioReliance Corporation

GeoVax Announces Appointment of David Dodd as Chairman, President and Chief Executive Officer

8/14/2018

GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that David A. Dodd has been appointed President and Chief Executive Officer, effective September 1, succeeding Robert McNally, PhD, who has announced his retirement.
BioReliance Corporation Licenses B-CLEAR Technology From Qualyst, Inc. Transporter Solutions For Drug Transporter Studies

4/21/2015
Conatus Pharmaceuticals Inc. And BioReliance Corporation Present Key Emricasan Preclinical Safety Results At Society Of Toxicology Annual Meeting

3/24/2015
BioReliance Corporation Introduces Advanced In Vitro ADME And Toxicology Services Designed To Improve Drug Safety And Efficacy

10/16/2014
Sigma-Aldrich Corporation Release: BioReliance Corporation Opens New U.S. Clearance Services Laboratories; Completes Global Facility Upgrade Plan

9/4/2013
Archie Cullen Named President of BioReliance Corporation

3/5/2013
Sigma-Aldrich Corporation Completes Acquisition of BioReliance Corporation

2/1/2012
Sigma-Aldrich Corporation to Acquire BioReliance Corporation for $350 Million Cash

1/9/2012
BioReliance Corporation Enhances Toxicology Expertise

9/13/2011
BioReliance Corporation Announces ToxCast Award

2/8/2011
Marilyn J. Aardema, PhD Joins BioReliance Corporation as Chief Scientific Officer, Toxicology

11/15/2010
BioReliance Corporation Launches a Validated Assay to Detect Calicivirus 2117 in Biological Samples

10/6/2009
BioReliance Corporation Establishes a Liaison Office in India

5/12/2009
Innovations in Toxicology at BioReliance Corporation: 23rd Annual Genotoxicity and Carcinogenicity Workshop

2/20/2009
BioReliance Corporation Announces Agreement with Barr Pharmaceuticals, Inc. to Supply Bulk Virus for the Manufacture of Adenovirus Vaccine for the U.S. Department of Defense

1/6/2009
BioReliance Corporation Announces First Commercial Use of HyMy(TM) Assay

11/20/2008
BioReliance Corporation Announces IMP Manufacturing Agreement with Provecs Medical GmbH

11/18/2008
BioReliance CorporationAnnounces that Sarah Sheridan, Ph.D. Will Deliver a Poster Presentation at the 16th Annual European Society of Gene and Cell Therapy Conference

11/13/2008
BioReliance Corporation Introduces New Protein Array Platform -- ReliArray(TM)

11/7/2008
BioReliance Corporation Appoints Andrew Paterson Ph.D. as Senior Director/General Manager for UK Operations

10/14/2008